A systematic analysis of 37 randomized controlled trials encompassing 4,218 children and adolescents reveals significant gaps in evidence for pharmacological obesity treatments in young populations. The review, spanning studies with minimum six-month follow-ups, found that most research focused on adolescents rather than younger children, with only eight studies actually including both age groups despite eleven planning to do so. This represents the most comprehensive assessment to date of pediatric obesity medications, examining not just weight outcomes but also quality of life and long-term adverse events. The findings underscore a critical knowledge vacuum in pediatric obesity management. Unlike adult obesity treatments where several FDA-approved medications show clear efficacy, the pediatric landscape remains largely uncharted territory. This is particularly concerning given rising childhood obesity rates globally and the long-term health consequences that track from adolescence into adulthood. The review's emphasis on adverse events and discontinuation rates highlights safety concerns that are especially pertinent in developing populations. The limited inclusion of younger children suggests researchers and clinicians remain cautious about pharmaceutical interventions during critical growth periods, reflecting both ethical considerations and regulatory challenges in pediatric drug development.